178 results on '"Scholl, Sebastian"'
Search Results
2. Validating genetic variants in innate immunity linked to infectious events in acute myeloid leukemia post-induction chemotherapy
3. Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
4. Targeting protein kinase C-α prolongs survival and restores liver function in sepsis: Evidence from preclinical models
5. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia
6. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
7. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study
8. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
9. Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia
10. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
11. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
12. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
13. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
14. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
15. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia
16. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
17. Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia
18. Application of a nanoindentation-based approach for parameter identification to a crystal plasticity model for bcc metals
19. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
20. Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
21. Significance of separations occurring in mechanical testing of thermomechanical rolled pipeline steels
22. Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma
23. Primär- und Rezidivtherapie akuter Leukämien
24. Ziele und Optionen der palliativen Therapie der akuten myeloischen Leukämie
25. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
26. Standardizing Nutritional Care for Cancer Patients: Implementation and Evaluation of a Malnutrition Risk Screening.
27. A comprehensive quantitative characterisation of the multiphase microstructure of a thick-section high strength steel
28. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
29. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
30. A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).
31. Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation
32. No impact of time from diagnosis to treatment on survival in newly diagnosed AML treated with venetoclax-based regimens
33. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed / refractory large B-cell lymphoma: findings from a German monocentric study.
34. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
35. Synergistic Effects of the RAR alpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation.
36. PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
37. P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)
38. P474: FUNCTIONAL (PHOSPHO-)PROTEOMICS OF DRUG RESPONSE IN ACUTE MYELOID LEUKEMIA
39. S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
40. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes.
41. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL.
42. Modeling Bainite Dual-Phase Steels: A High-Resolution Crystal Plasticity Simulation Study
43. Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
44. Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
45. Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
46. Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)
47. Automated Classification of Granular Bainite and Polygonal Ferrite by Electron Backscatter Diffraction Verified through Local Structural and Mechanical Analyses
48. Local Strength of Bainitic and Ferritic HSLA Steel Constituents Understood Using Correlative Electron Microscopy and Micro-compression Testing
49. Primär- und Rezidivtherapie akuter Leukämien
50. Ziele und Optionen der palliativen Therapie der akuten myeloischen Leukämie
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.